TABLE 1.
Solutions used for this report
| K2EGTA | K2CaEGTA | CaPr2 | Na2MgATP | Na2K2ATP | MgPr2 | Na2CP | NaADP | K1.5Pi | KPr | NaPr | NaN3 | A2P5 | CK | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solutions | mM | mM | mM | mM | mM | mM | mM | mM | mM | mM | mM | mM | mM | unit/ml |
| Skinning | 5 | – | – | 2 | 5 | – | – | – | – | – | 132 | – | – | – |
| Relax | 5.03 | 0.97 | – | 2 | 5 | – | – | – | 8 | 55 | 51 | 10 | – | – |
| Rigor | – | – | – | – | – | – | – | – | 8 | 102 | 75 | – | – | – |
| WP | – | – | – | 5.83 | 1.45 | – | 15 | – | 0 | 109 | 0.4 | 10 | – | 320 |
| 5S0P | – | 6 | 0.179 | 5.83 | 1.45 | – | 15 | – | 0 | 91 | 0.5 | 10 | – | 320 |
| 5S32P | – | 6 | 0.170 | 5.70 | 1.45 | – | 15 | – | 32 | 17 | 0.7 | 10 | – | 320 |
| WS | – | – | – | – | 0.84 | – | 15 | – | 8 | 103 | 13 | 10 | – | 320 |
| 0S8P | 0.017 | 5.98 | – | – | – | 0.85 | 15 | – | 8 | 88 | 15 | 10 | – | 320 |
| 5S8P* | – | 6 | 0.174 | 5.79 | 1.45 | – | 15 | – | 8 | 73 | 0.5 | 10 | – | 320 |
| WD | – | – | – | 2.78 | 0.10 | – | – | – | 8 | 116 | 39 | 10 | 0.2 | – |
| 0D2S | – | 6 | 0.055 | 2.72 | 0.182 | – | – | – | 8 | 97 | 39 | 10 | 0.2 | – |
| 3D2S | – | 6 | 0.205 | 2.86 | – | 2.786 | – | 11.9 | 8 | 62 | 21 | 10 | 0.2 | – |
CP = creatine phosphate, Pi = phosphate, Pr = propionate, CK = creatine kinase, A2P5 = P1,P5-diadenosine pentaphosphate. In addition to the above, 10 mM MOPS (morpholinopropane sulfonic acid) is added to all solutions, and pH adjusted to 7.00. The ionic strength of all solutions is 200 mM. pCa of relaxing solution is 7.00; pCa of all activating solutions is 4.40. Mg2+ concentration of all activating solutions is 0.5 mM. nSmP notation indicates activating solution composition, where n = [MgATP2−] and m = [Pi]total. *5S8P solution is the same as the standard activating solution, and it contains 5 mM MgATP2− and 8 mM total Pi.